- Oops!Something went wrong.Please try again later.
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has agreed to provide a license to Laboratoire Aguettant to commercialize Dzuveo in Europe and give AcelRx two prefilled syringe product candidates for the U.S.
Under the Dzuveo licensing agreement, Aguettant will have the right to commercialize Dzuveo in Europe.
AcelRx will up to $55 million in a combination of up-front and sales-based milestone payments, along with revenue share payments ranging from 35% to 45% of net sales.
Under the terms of a separate U.S. licensing agreement, AcelRx obtained the rights to file marketing applications (subject to approval) and commercialize two of Aguettant's EU-approved, prefilled syringe ephedrine and phenylephrine products.
Aguettant will receive up to $24 million in sales-based milestone payments at various annual sales levels up to $60 million, along with revenue share payments of 40 to 45%.
Dzuveo is indicated for the management of acute pain in hospital settings.
Price Action: ACRX shares are up 4.92% at $1.28 during the premarket session on the last check Wednesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.